Inhibrx IncNASDAQ:INBX
- LAST PRICE19.9300
- TODAY'S CHANGE (%)-0.3800 (-1.8710%)
- Bid / Lots19.8900/ 2
- Ask / Lots19.9800/ 5
- Open / Previous Close20.3000 / 20.3100
- Day Range
- 52 Week Range
- Volume68,280
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INBX |
|---|---|---|
| 09:32 ET | 1973 | 20.69 |
| 09:34 ET | 400 | 20.68 |
| 09:36 ET | 200 | 20.19 |
| 09:38 ET | 100 | 20.285 |
| 09:39 ET | 900 | 20.13 |
| 09:41 ET | 200 | 20.4 |
| 09:50 ET | 100 | 20.31 |
| 09:54 ET | 300 | 20.42 |
| 09:56 ET | 2829 | 20.31 |
| 09:57 ET | 5582 | 20.44 |
| 10:01 ET | 200 | 20.385 |
| 10:03 ET | 300 | 20.38 |
| 10:06 ET | 100 | 20.49 |
| 10:08 ET | 200 | 20.38 |
| 10:12 ET | 100 | 20.39 |
| 10:14 ET | 485 | 20.45 |
| 10:15 ET | 100 | 20.46 |
| 10:17 ET | 200 | 20.45 |
| 10:19 ET | 300 | 20.43 |
| 10:28 ET | 300 | 20.35 |
| 10:32 ET | 100 | 20.315 |
| 10:33 ET | 498 | 20.14 |
| 10:35 ET | 100 | 20.13 |
| 10:37 ET | 200 | 20.26 |
| 10:44 ET | 400 | 20.14 |
| 10:46 ET | 200 | 20.16 |
| 10:57 ET | 400 | 20.17 |
| 11:04 ET | 110 | 20.19 |
| 11:06 ET | 100 | 20.25 |
| 11:08 ET | 100 | 20.25 |
| 11:11 ET | 101 | 20.275 |
| 11:15 ET | 800 | 20.26 |
| 11:18 ET | 1090 | 20.295 |
| 11:20 ET | 500 | 20.35 |
| 11:22 ET | 344 | 20.36 |
| 11:26 ET | 4937 | 20.3 |
| 11:27 ET | 8209 | 20.3 |
| 11:29 ET | 200 | 20.31 |
| 11:31 ET | 2518 | 20.2 |
| 11:33 ET | 4398 | 20.1 |
| 11:36 ET | 566 | 20.16 |
| 11:38 ET | 130 | 20.26 |
| 11:40 ET | 300 | 20.41 |
| 11:44 ET | 100 | 20.33 |
| 11:45 ET | 100 | 20.42 |
| 11:49 ET | 720 | 20.34 |
| 11:51 ET | 163 | 20.2796 |
| 11:56 ET | 500 | 20.29 |
| 12:00 ET | 400 | 20.24 |
| 12:07 ET | 100 | 20.3 |
| 12:09 ET | 100 | 20.225 |
| 12:34 ET | 200 | 20.23 |
| 12:36 ET | 200 | 20.24 |
| 12:50 ET | 100 | 20.24 |
| 12:52 ET | 459 | 20.13 |
| 12:54 ET | 100 | 20.185 |
| 12:59 ET | 500 | 20.19 |
| 01:01 ET | 400 | 20.19 |
| 01:08 ET | 1520 | 20.105 |
| 01:14 ET | 100 | 20.09 |
| 01:17 ET | 600 | 20.015 |
| 01:21 ET | 300 | 20.01 |
| 01:30 ET | 400 | 20.06 |
| 01:35 ET | 400 | 19.98 |
| 01:39 ET | 600 | 20.02 |
| 01:46 ET | 100 | 19.985 |
| 01:48 ET | 200 | 19.93 |
Mar 13, 2023
BRIEF-Inhibrx Inc Does Not Have Exposure To Silicon Valley Bank, from 8:01AM ET on Monday Mar 13, 2023 by Thomson Reuters
8:01AM ET on Monday Mar 13, 2023 by Thomson Reuters
Mar 8, 2023
JMP Securities Adjusts Price Target on Inhibrx to $35 From $40, Maintains Market Outperform Rating, from 10:12AM ET on Wednesday Mar 08, 2023 by MT Newswires
10:12AM ET on Wednesday Mar 08, 2023 by MT Newswires
Mar 6, 2023
BRIEF-Inhibrx Reports Q4 And Fiscal Year 2022 Financial Results, from 6:43PM ET on Monday Mar 06, 2023 by Thomson Reuters
6:43PM ET on Monday Mar 06, 2023 by Thomson Reuters-- Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $274,000, from 4:10PM ET on Monday Mar 06, 2023 by MT Newswires
4:10PM ET on Monday Mar 06, 2023 by MT NewswiresInhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results, from 4:05PM ET on Monday Mar 06, 2023 by PR Newswire
4:05PM ET on Monday Mar 06, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibrx Inc | 884.9M | -5.5x | --- |
EQRx Inc | 889.3M | -5.2x | --- |
Verve Therapeutics Inc | 907.1M | -5.0x | --- |
BELLUS Health Inc | 908.0M | -10.9x | --- |
Crinetics Pharmaceuticals Inc | 858.8M | -4.9x | --- |
Structure Therapeutics Inc | 913.0M | -15.1x | --- |
Company Information
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Contact Information
- Headquarters
- 11025 N. Torrey Pines Road, Suite 200LA JOLLA, CA, United States 92037
- Phone
- 858-795-4220
- Fax
- 302-636-5454
Executives
- Chairman of the Board of Director, President, Chief Executive Officer, Co-Founder
- Mark Lappe
- Co-Founder, Chief Scientific Officer
- Brendan Eckelman
- Chief Financial Officer
- Kelly Deck
- Independent Director
- Douglas Forsyth
- Independent Director
- Jon Kayyem
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $884.9M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 43.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.62 |
Book Value | $1.33 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | 403.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,890.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
